Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, announced that its portfolio company, LAVA Therapeutics, has successfully achieved pricing of its Nasdaq initial public offering, expected to result in gross proceeds of approximately $100 million.
March 25, 2021
· 2 min read